Sarepta says FDA raises doubt about drug trial, shares drop 39 pct
Nov 12 (Reuters) - Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had raised concerns about the trial for the company's experimental muscle disorder drug and considered the marketing application for the treatment to be premature. Sarepta shares fell 39 percent to $22.20
Read more